EPIDEMIOLOGY OF BREAST CANCER IN AFRICA
breast cancer in Nigeria. Breast Cancer Res Treat. 2008; 110:183–188. 7. Huo D et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009; 27:4515–4521 30
Tags:
Breast, Cancer, Triple, Negative, Breast cancer, Triple negative breast cancer
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Documents from same domain
PRINCIPLES OF CHEMOTHERAPY IN CANCER
oncologypro.esmo.org1. NEOADJUVANT CHEMOTHERAPY [PREOPERATIVELY] Rationale •To make non-operable tumors operable •To achieve organ preservation •To select sensitivity for specific treatment (biomarkers) 2. ADJUVANT CHEMOTHERAPY [POSTOPERATIVELY] Rationale •To kill micrometastatic disease •To increase disease-free survival 3. PALLIATIVE CHEMOTHERAPY
THE LUGANO CLASSIFICATION
oncologypro.esmo.orgBONE MARROW EVALUATION • HL If PET-CT is performed, bone marrow biopsy no longer indicated for HL • DLBCL Biopsy if the PET is negative and identifying a discordant histology is important for patient management • Other subtypes ~2.5 cm unilateral bone marrow biopsy is recommended, along with immunohistochemistry and flow cytometry at
CYP3A4 Inhibitor/Inducer Drug-drug Interactions for all ...
oncologypro.esmo.orgAfter discontinuation of a strong CYP3A4 inhibitor resume the dose that was taken prior to initiating the strong CYP3A4 inhibitor Avoid concurrent use of strong CYP3A inducers Crizotinib Ketoconazole Rifampicin Extreme caution should be taken if co-administration with a CYP3A4 inhibitor is unavoidable, the crizotinib dose should be
CLINICAL TRIAL ENDPOINTS - OncologyPRO
oncologypro.esmo.orgESMO Clinical Trials Tips and Tricks: Clinical Trial Endpoints Author: Ian Tannock, Steinar Aamdal, Dirk Arnold, Urania Dafni, Ulrich Keilholz, Morten Mau-Sørensen, Piotr Rutkowski, Stefan Sleijfer Subject: ESMO Clinical Trials Tips and Tricks: Clinical Trial Endpoints Created Date: 12/4/2015 12:53:31 PM
UNDERSTANDING CLINICAL TRIAL STATISTICS
oncologypro.esmo.orgUNDERSTANDING CLINICAL TRIAL STATISTICS. Prepared by Urania Dafni, Xanthi ... EaSt 6.3.1: a software package for the design and interim monitoring of group sequential clinical trials, Cytel Software Corporation, Cambridge, MA, ... Understanding Clinical Trials Statistics
Design, Understanding, Clinical, Trail, Understanding clinical trials, Understanding clinical
Related documents
The New AJCC 8th Edition Breast Cancer Staging
www.pathcme.com“Luminal Cancer”* - ER positive/HER2 negative “Triple Negative Breast Cancer” (TNBC)* - ER negative/HER2 negative “HER2 Cancer”* - ER positive or negative/HER2 positive The expression (or non- expression) of ER and HER2 is highly correlated with the additional expression of dozens to hundreds of other genes as
Breast, Cancer, Triple, Negative, Breast cancer, Triple negative breast cancer
BC Cancer Protocol Summary for NEOAdjuvant Therapy for ...
www.bccancer.bc.ca• Previously untreated triple negative breast cancer patients with any node positive breast cancer or tumour size ≥ 2.5 cm with clinically negative nodes (Stage IIA or greater). EXCLUSIONS: Severe cardiovascular disease with LVEF less than 45% AST and/or ALT greater than 3X ULN the Upper Limit of Normal (ULN)
Breast, Cancer, Triple, Negative, Breast cancer, Triple negative breast cancer
Genetic Testing for Hereditary Cancer - UHCprovider.com
www.uhcprovider.como Triple-Negative Breast Cancer diagnosed at any age; or o Lobular breast cancer with personal or family history of diffuse gastric cancer; or Individual has a Tyrer -Cuzick, BRCAPro or Penn11 Score of 2.5% or greater for a BRCA1/2 pathogenic variant. Genetic testing Panels for . High Penetrance Breast Cancer Susceptibility Genes. for ...
Breast, Cancer, Triple, Negative, Breast cancer, Triple negative breast cancer
Keytruda (pembrolizumab - European Medicines Agency
www.ema.europa.euTriple-negative breast cancer A main study compared Keytruda plus chemotherapy with placebo and chemotherapy in 847 patients with previously untreated triple-negative breast cancer that could not be removed surgically or had spread. Among patients with high levels of PD-L1, those in the Keytruda group lived for almost 10
Breast, Cancer, Triple, Negative, Keytruda, Triple negative breast cancer
or - Merck | Home
www.merck.coma kind of cancer called triple-negative breast cancer (TNBC). KEYTRUDA may be used with chemotherapy medicines when your breast cancer: o has returned and cannot be removed by surgery or has spread, and o tests positive for “PD-L1”. Before receivingKEYTRUDA, tell your healthcare providerabout all of your medical conditions, including if you:
Breast, Cancer, Triple, Negative, Breast cancer, Triple negative breast cancer
HIGHLIGHTS OF PRESCRIBING INFORMATION See Full …
www.gilead.com• Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. (1.1, 14.1) • Locally advanced or metastatic urothelial cancer (mUC) who have previously received a platinum-containing chemotherapy and either
Breast, Cancer, Triple, Negative, Triple negative breast cancer
Breast Cancer Risk and Prevention
www.cancer.orgAmerican women are more likely to have the less common triple-negative breast cancer. Being taller Many studies have found that taller women have a higher risk of breast cancer than shorter women. The reasons for this aren’t exactly clear, but it may have something to
Breast, Cancer, Triple, Negative, Breast cancer, Triple negative breast cancer